NASDAQ:CDTX
Cidara Therapeutics Stock News
$12.63
-0.370 (-2.85%)
At Close: Apr 26, 2024
Analysts Offer Insights on Healthcare Companies: PolarityTE (PTE) and Entasis Therapeutics Holdings (ETTX)
06:34pm, Thursday, 12'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (PTE) and Entasis Therapeutics Holdings (ETTX)
Invitae (NVTA) Gets a Buy Rating from Oppenheimer
01:44am, Wednesday, 11'th Mar 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Invitae (NVTA) yesterday and set a price target of $32.00. The company's shares closed last
Invitae (NVTA) Gets a Buy Rating from Oppenheimer
01:44am, Wednesday, 11'th Mar 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Invitae (NVTA – Research Report) yesterday and set a price target
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
10:55am, Wednesday, 04'th Mar 2020
SAN DIEGO, March 04, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of.
Cidara Therapeutics (NASDAQ:CDTX) vs. Editas Medicine (NASDAQ:EDIT) Head to Head Comparison
06:12am, Wednesday, 04'th Mar 2020
Cidara Therapeutics (NASDAQ:CDTX) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of t
Oppenheimer Maintains Their Buy Rating on Athenex (ATNX)
07:34pm, Thursday, 27'th Feb 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Athenex (ATNX) today and set a price target of $23.00. The company's shares closed last
Oppenheimer Maintains Their Buy Rating on Athenex (ATNX)
07:33pm, Thursday, 27'th Feb 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Athenex (ATNX – Research Report) today and set a price target
Cidara Therapeutics (CDTX) Upgraded to Buy: What Does It Mean for the Stock?
05:00pm, Thursday, 27'th Feb 2020
Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Are Bullish on Top Healthcare Picks
08:43am, Thursday, 27'th Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novavax (NVAX) and Intercept Pharma (ICPT) with bullish
Oppenheimer Reaffirms Their Buy Rating on Vericel (VCEL)
11:19pm, Sunday, 23'rd Feb 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Vericel (VCEL – Research Report) today and set a price target
Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences
01:00pm, Tuesday, 18'th Feb 2020
SAN DIEGO, Feb. 18, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics to improve the standard of care for patients facing severe.
Cidara Therapeutics Announces Closing of Rights Offering
10:30pm, Wednesday, 12'th Feb 2020
SAN DIEGO, Feb. 12, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced the closing of its previously announced rights offering (the “Rights Offering”)..
Some Cidara Therapeutics (NASDAQ:CDTX) Shareholders Have Taken A Painful 74% Share Price Drop
11:25am, Tuesday, 11'th Feb 2020
While not a mind-blowing move, it is good to see that the Cidara Therapeutics, Inc. (NASDAQ:CDTX) share price has...
Healthcare tops premarket losers as Coronavirus worries deepen
02:15pm, Tuesday, 28'th Jan 2020
NanoViricides (NYSEMKT:NNVC) -23% after coronavirus breakout.Allied Healthcare Products (NASDAQ:AHPI) -19% after coronavirus breakout.Aethlon Medical (NASDAQ:AEMD) -16% after coronavirus break
The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
12:12pm, Tuesday, 28'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmace
